The reference pricing: impact in the pharmaceutical market

被引：0
|
作者：
Verpillot, Elise [1 ]
机构：
[1] Univ Victor Segalen Bordeaux 2, ISPED, GREGSAP, F-33076 Bordeaux, France
来源：
REVUE D ECONOMIE POLITIQUE | 2009年 / 119卷 / 05期
关键词：
reference pricing; vertical differentiation; drugs; PRICES;
D O I：
10.3917/redp.195.0795
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
Increases in national pharmaceutical spending have led governments to adopt new measures aimed at promoting price competition. One such approach to regulate the pharmaceutical market is reference pricing, A reference price system categorises products into groups so that the reference price is the maximum reimbursement of the third party payer for all products in that group. Using a vertical product differentiation model, we deduce that the reference price system can generate a drug price cut, However the impact on public expenditures is uncertain.
引用
收藏
页码：795 / 816
页数：22
相关论文
共 50 条
  • [31] The impact of reference pricing on clinical lipid control
    Thomas, MC
    Mann, J
    Williams, S
    [J]. NEW ZEALAND MEDICAL JOURNAL, 1998, 111 (1071) : 292 - 294
  • [32] The impact of reference price effect on pricing decisions
    Wang, Chen-hao
    Liu, Yong
    Pan, Zi-yi
    [J]. ASIA PACIFIC JOURNAL OF MARKETING AND LOGISTICS, 2024, 36 (05) : 1150 - 1170
  • [33] The impact of generic reference pricing in Italy, a decade on
    Simone Ghislandi
    Patrizio Armeni
    Claudio Jommi
    [J]. The European Journal of Health Economics, 2013, 14 : 959 - 969
  • [34] The impact of network topology and market structure on pricing
    Chen, Ying-Ju
    Zenou, Yves
    Zhou, Junjie
    [J]. JOURNAL OF ECONOMIC THEORY, 2022, 204
  • [35] The Impact of Takeovers on the Acquiring Firms in the Pharmaceutical Market
    Raciborski, Michal
    [J]. JOURNAL OF COMPETITIVENESS, 2017, 9 (01) : 89 - 102
  • [36] THE IMPACT OF THE GERMAN PHARMACEUTICAL MARKET REORGANISATION ACT (AMNOG) ON THE GERMAN REFERENCE PRICE MARKET - TRENDS TWO YEARS AFTER THE INTRODUCTION OF THE AMNOG
    Eheberg, D.
    Batscheider, A.
    Lebioda, A.
    Plantoer, S.
    Fricke, F. U.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A324 - A324
  • [37] MODELLING THE IMPACT OF PRICING EXCEPTIONS AND PROTECTIONS ON PHARMACEUTICAL EXPENDITURE IN GREECE
    Souliotis, K.
    Golnas, P.
    Theodoratou, D.
    Golna, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S258 - S258
  • [38] New Zealand's pharmaceutical reference-pricing strategy may backfire
    Menkes, D
    [J]. LANCET, 2000, 355 (9203): : 558 - 558
  • [39] Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
    Brekke, Kurt R.
    Holmas, Tor Helge
    Rune Straume, Odd
    [J]. JOURNAL OF PUBLIC ECONOMICS, 2011, 95 (7-8) : 624 - 638
  • [40] The impact of compounding on bond pricing with alternative reference rates
    Cziraky, Dario
    Ponikvar, Ana
    [J]. JOURNAL OF RISK, 2021, 23 (06): : 37 - 66
12345